Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on January 8, 2018, reporting events occurring on January 4, 2018. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements, specifically the grant of stock options to key executives.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the terms of the stock option grants:
- Strike Price: $2.06 per share (based on the Nasdaq closing price on January 4, 2018).
- Total Options Granted: 1,130,000 shares.
- Option Term: 10 years.
Material Changes
The material change reported is the execution of equity incentive grants under the 2011 Equity Incentive Plan. The grants were distributed as follows:
- Will McGuire (President and CEO): 450,000 options
- Robert Greenberg, M.D., Ph.D. (Chairman): 140,000 options
- Steve Okland (Commercial VP, U.S. and Canada): 140,000 options
- David Jacques (VP – R&D): 125,000 options
- Ted Randolph (VP of Manufacturing): 45,000 options
- Greg Cosendai (VP Clinical Affairs): 65,000 options
- Amit Kukreja (VP Global Reimbursement & Market Access): 65,000 options
- Frank Vandeputte (VP and GM, EMEA): 30,000 options
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies. The vesting schedule is defined as 25% on the one-year anniversary of the grant date, followed by 6.25% each calendar quarter thereafter, contingent upon continued employment.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2011 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current trading price of Second Sight Medical Products, Inc. stock relative to the $2.06 strike price to evaluate the intrinsic value of the grants.
- Review the company's most recent 10-K or 10-Q for actual financial performance, as this 8-K contains no operational or financial results.
- Check for any subsequent filings regarding the resignation or termination of the named executives, as vesting is contingent on continued employment.